X4 Pharmaceuticals, Inc., is a high-risk pharmaceutical company based in the United States of America. Specializing in rare diseases and conditions related to immune system dysfunction, X4 Pharmaceuticals focuses on developing innovative therapeutics with a key focus on ESG criteria. The company's leading clinical candidate, mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4, aims to provide a once-daily oral therapy that enhances the mobilization of white blood cells from the bone marrow into the bloodstream. Additionally, X4 Pharmaceuticals is advancing two pre-clinical candidates, X4P-003 and X4P-002, which are CXCR4 antagonists with unique properties.